Opinion
Video
Updates from the SAHARA Trial at AAO 2023
Richard Adler, MD, FACS, provides insights on data presented at AA0 2023, from a study comparing results of the ARMOR procedure versus treatment with cyclosporine ophthalmic emulsion 0.05% in patients with dry eye disease.
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses results from the SAHARA trial evaluating an investigational procedure called Aqueous Retention and Meibomian Gland Outflow Restoration (ARMOR) for dry eye disease. The ARMOR procedure involves debridement, thermal compression, and expression of the meibomian glands in the eyelids to improve meibum quality and reduce tear evaporation.
The SAHARA trial compared ARMOR to Restasis (cyclosporine ophthalmic emulsion 0.05%) for improving tear breakup time (TBUT) and symptoms in evaporative dry eye. TBUT measures tear evaporation rate. The study found ARMOR showed clinically and statistically significant improvements in both TBUT and symptoms compared with Restasis over 12 weeks.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
